Baxter price target raised to $54 from $45 at Stifel

Stifel analyst Rick Wise raised the firm’s price target on Baxter to $54 from $45 and keeps a Buy rating on the shares. Baxter’s Q1 benefitted from stable-to-improving macro conditions, which led to it delivering a modest top-line and more-meaningful bottom-line beat, the analyst tells investors. Stifel is currently feeling "cautiously-optimistic" about the company’s setup to the 2023 year and suspects there could be further outperformance potential ahead.